Posted: June 22, 2009

NanoViricides, Inc. CEO Invited to Speak at NanoBio 2009 Conference

(Nanowerk News) NanoViricides, Inc. announced today that its CEO, Dr. Eugene Seymour, has been invited to present a talk, and, in addition, participate in presenting a workshop on “Nanoparticle Formulation: principles and applications”, at the 3rd International Congress of NanoBiotechnology & NanoMedicine (NanoBio 2009) to be held in San Francisco on June 22-24, 2009. The conference is sponsored by, among others, The National Cancer Institute, the National Institute of Standards and Technology, the Lawrence Berkeley National Laboratory and Stanford University.
Dr Seymour plans to discuss the nature of the Company’s nanoviricide™ drug technology and platform as well as results of various laboratory and animal studies against different viruses. Dr. Seymour will summarize the Company’s successes against multiple types of influenza viruses including different H5N1 bird flu viruses and H1N1 virus similar to the current pandemic-causing H1N1. He will also talk about the Company’s successes against HIV, adenoviral epidemic keratoconjunctivitis (EKC), Ebola and Rabies. In addition to these programs, the Company is also developing nanoviricide drugs against dengue viruses. His talk is scheduled for Tuesday, the 23rd June, 2009. The workshop takes place in two sessions on Monday, the 22nd.
About NanoViricides
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
Source: NanoViricides (press release)
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: